石四藥(02005.HK)斥逾3.5億人幣收購辰欣藥業6.1%股權
石四藥集團(02005.HK)公佈,公司之全資附屬石家莊四藥,向天津乾鼎企業管理合夥企業購買2,766.1萬股目標股份,相當於目標公司辰欣藥業(603347.SH)之6.1015%股權,總代價爲3.54億元人民幣(下同)。
收購事項之代價爲每股12.8元,較目標公司股份前一交易日在上交所收市價每股12.15元溢價約5.35%。
目標集團主要從事化學制劑爲主藥品的研發、生產和銷售業務,產品涵蓋大容量注射劑(包括非PVC軟袋、塑瓶、直立袋、玻璃瓶)、凍乾粉針劑、小容量注射劑、片劑及膠囊劑等五大劑型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.